Quoin Pharmaceuticals (QNRX) Non Operating Interest Expenses (2021)
Quoin Pharmaceuticals' (QNRX) quarterly Non Operating Interest Expenses came in at -$59000.0 in Q4 2021, down 129.13% quarter-over-quarter from $202514.0 in Q2 2021.
Powered by 
Analysis
Quoin Pharmaceuticals (QNRX) Non Operating Interest Expenses (2021) Analysis & Trends
Quoin Pharmaceuticals has disclosed Non Operating Interest Expenses across 1 years of filings, most recently posting -$59000.0 for Q4 2021.
- In Q4 2021, Non Operating Interest Expenses changed N/A year-over-year to -$59000.0; the TTM figure through Sep 2022 stood at -$59000.0 (changed N/A YoY), while the FY2021 annual figure was $275000.0, up 484.85% from the prior year.
- Non Operating Interest Expenses came in at -$59000.0 for Q4 2021 at Quoin Pharmaceuticals, down from $202514.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $202514.0 in Q2 2021 to a low of -$59000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 120.70 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -13.26 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 396.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -41.02 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 6.66 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 3,000.00 |
| 10 | Quoin Pharmaceuticals | 660,541.34 | 660,541.34 | - | - |